- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
- Interventions
- Eflornithine (Dose Level -1), Eflornithine (Dose Level 2), Temozolomide
- Drug
- Lead sponsor
- Orbus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 356
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Glioblastoma Multiforme, High-Grade Glioma
- Interventions
- Gliadel wafer, Temozolomide, External Beam Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Methodist Healthcare - Memphis
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glioblastoma
- Interventions
- Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI
- Radiation · Drug · Behavioral + 1 more
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Glioblastoma
- Interventions
- CART-EGFRvIII T cells, Pembrolizumab
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab, Tarceva, Temozolomide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
- Interventions
- gefitinib, radiation therapy, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Interventions
- Pamiparib, Olaparib, Radiation therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
- Other · Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Pamiparib, TMZ, Radiation
- Drug · Radiation
- Lead sponsor
- BeiGene USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Newly Diagnosed MGMT Unmethylated Glioblastoma
- Interventions
- D2C7-IT, 2141-V11
- Drug
- Lead sponsor
- Darell Bigner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- FMISO, MRI, PET, MRS
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 9 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- capecitabine, radiation therapy
- Drug · Radiation
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 12
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Brain and Central Nervous System Tumors, Cerebral Edema
- Interventions
- Boswellia serrata extract, cyanocobalamin
- Drug · Dietary Supplement
- Lead sponsor
- Ali Altunkaya
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 202
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
- Biological · Drug · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
- Interventions
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Atezolizumab, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Adavosertib, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Valproic acid, Bevacizumab, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 6
- States / cities
- Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- oxaliplatin, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glioblastoma
- Interventions
- Not listed
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Glioblastoma (GBM)
- Interventions
- anti-EGFR bispecific-armed T cells, Low-Intensity Focused Ultrasound
- Drug · Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioblastoma Multiforme
- Interventions
- Disulfiram, Copper Gluconate, Surgery, Radiation, Temozolomide
- Drug · Procedure · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri